[1] CHUENG T, SUAREZ J F, CAMARGO J F. Efficacy and tolerability of fosfomycin in prevention of recurrent urinary tract infections among kidney transplant recipients[J]. Transpl Infect Dis,2019,21(2):e13042.
[2] WAGENLEHNER F, WULLT B, BALLARINI S, et al. Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT)[J]. Expert Rev Pharmacoecon Outcomes Res,2018,18(1):107-117.
[3] MATTHEWS S J, LANCASTER J W. Urinary tract infections in the elderly population[J]. Am J Geriatr Pharmacother,2011,9(5):286-309.
[4] NG Q X, YONG C, LOKE W, et al. Escitalopram-induced liver injury: a case report and review of literature[J]. World J Hepatol,2019,11(10):719-724.
[5] TESCHKE R, EICKHOFF A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps[J]. Front Pharmacol,2015,6:72.
[6] ZHOU Y, SHEN J X, LAUSCHKE V M. Comprehensive evaluation of organotypic and microphysiological liver models for prediction of drug-induced liver injury[J]. Front Pharmacol,2019,10:1093.
[7] SMYK D S, BOGDANOS D P, KRIESE S, et al. Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside[J]. Clin Res Hepatol Gastroenterol,2012,36(2):110-121.
[8] KIRIYAMA K, USUI T, TAKEMURA T, et al. A case of rapid-onset antimitochondrial antibody-positive autoimmune hepatitis possibly triggered by a urinary tract infection[J]. Nihon Shokakibyo Gakkai Zasshi,2010,107(2):270-277.
[9] OHNO N, OTA Y, HATAKEYAMA S, et al. A patient with E. coli-induced pyelonephritis and sepsis who transiently exhibited symptoms associated with primary biliary cirrhosis[J]. Intern Med,2003,42(11):1144-1148. |
